Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
Rhea-AI Summary
Syndax (Nasdaq:SNDX) announced that 12 abstracts featuring Revuforj® (revumenib) were accepted for EHA 2026, covering real‑world, frontline, relapsed/refractory, and post‑transplant acute leukemia settings.
Data span KMT2Ar, NPM1m, and NUP98r leukemias and include trials in progress, reinforcing Syndax’s focus on menin inhibition in AML.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – SNDX
On the day this news was published, SNDX declined 4.54%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SNDX slipped 0.51% on above-average volume, while peers were mixed: ARDX -2.57%, BHVN -7.06%, VRDN +1.18%, VERA roughly flat. Moves do not indicate a unified biotech-sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Inducement stock grants | Neutral | -0.5% | New employee inducement option grants totaling 162,100 shares under 2023 plan. |
| Apr 30 | Quarterly earnings | Negative | -10.8% | Q1 2026 results showed strong revenue but continued net loss and high expenses. |
| Apr 24 | Earnings call notice | Neutral | +1.9% | Announcement of date and access details for upcoming Q1 2026 earnings call. |
| Apr 03 | Inducement stock grants | Neutral | -3.4% | Inducement stock options for new employees under 2023 Inducement Plan. |
| Mar 04 | Inducement stock grants | Neutral | -0.2% | Grant of 81,600 inducement options to three new employees with four-year vesting. |
Administrative and routine corporate updates have generally seen modest price moves, while fundamental updates like earnings have coincided with larger downside reactions.
Over the last six months, SNDX news has been dominated by routine inducement grants and financial reporting. An earnings update on Apr 30 detailing higher revenue but continued losses saw shares fall 10.83%, suggesting sensitivity to profitability and spending. Subsequent inducement grant releases on Mar 4, Apr 3, and May 6 triggered only small moves. Today’s EHA abstract update highlights expanding clinical data for Revuforj but arrives against a backdrop of prior earnings-driven volatility.
Market Pulse Summary
This announcement details 12 Revuforj abstracts accepted for EHA 2026, spanning real‑world evidence, frontline combinations, post‑transplant maintenance, and trials in progress across genetically defined acute leukemias. It reinforces Revuforj’s role as a first‑in‑class menin inhibitor with expanding clinical data. At the same time, the label carries important risks, including differentiation syndrome in 25% of patients and QTc prolongation in 36%. Investors may watch upcoming EHA presentations and longer‑term safety outcomes as key milestones.
Key Terms
menin inhibition medical
hematopoietic stem cell transplantation medical
pharmacokinetic medical
orphan drug designation regulatory
fast track designation regulatory
breakthrough therapy designation regulatory
differentiation syndrome medical
torsades de pointes medical
AI-generated analysis. Not financial advice.
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes –
– New real-world data show compelling outcomes and favorable tolerability with revumenib monotherapy and combination use –
– Two abstracts highlight encouraging results with revumenib in the post-transplant setting –
– Frontline and R/R revumenib combination data show deep responses, robust transplant rates, and favorable tolerability –
– Encouraging activity observed with revumenib in R/R NUP98r acute leukemia –
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today highlighted the release of 12 Revuforj® (revumenib) abstracts on the European Hematology Association (EHA) website in advance of the EHA 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden.
“The breadth of data accepted for presentation at EHA underscores the strength of revumenib’s clinical profile, with activity observed across the acute leukemia treatment continuum in KMT2Ar, NPM1m, and NUP98r acute leukemias,” said Nick Botwood, MBBS, Head of Research & Development and Chief Medical Officer at Syndax. “Given the need for therapies that can reduce the risk of relapse after stem cell transplantation, we are excited for the presentation of new data from the post-transplant setting showing favorable outcomes with revumenib compared to historical data. We also look forward to sharing additional frontline and R/R combination data showing high rates of MRD negativity, transplant, and favorable tolerability, supporting physician decision making and our ongoing pivotal trials.”
Dr. Botwood continued, “Collectively, these new data highlight our scientific leadership in menin inhibition and bolster our confidence that we are positioned to transform the treatment paradigm for
Key revumenib data accepted for presentation at EHA 2026:
- Findings from the ROAR study, a multicenter real-world study of revumenib in relapsed/refractory (R/R) acute leukemia.
- Updated frontline data from the Phase 1 trial of revumenib in combination with intensive chemotherapy in NPM1 mutated (NPM1m), KMT2A-rearranged (KMT2Ar), or NUP98-rearranged (NUP98r) acute myeloid leukemia (AML).
- Outcomes among adults and children with KMT2Ar, NPM1m, and NUP98r acute leukemia who received revumenib as maintenance following hematopoietic stem cell transplantation (HSCT).
- Updated R/R data from the SAVE trial of revumenib in combination with venetoclax and decitabine/cedazuridine in NPM1m, KMT2Ar, and NUP98r acute leukemia.
- Results in patients with R/R NUP98r acute leukemia treated with revumenib in AUGMENT-101 or via an expanded access program.
The accepted abstracts listed below are now available online on the EHA conference website. Copies of the poster presentations will be made available in the ‘Publications & Meetings Presentations’ section of the Syndax website after the embargo lifts.
Full list of revumenib abstracts accepted for EHA 2026 (all times in CEST):
| Abstract Titles | Presentation Details |
| Real-world evidence | |
| Revumenib in the real world: interim findings from the ROAR study in relapsed/refractory acute leukemia | Abstract Code: PF542 Poster Session 1 Friday, June 12, 6:45-7:45 pm |
| Frontline | |
| Revumenib + intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in KMT2A, NPM1, or NUP98: updated phase 1 results from SNDX-5613-0708 | Abstract Code: PF489 Poster Session 1 Friday, June 12, 6:45-7:45 pm |
| Post-HSCT maintenance | |
| Revumenib as maintenance for AML following allogeneic stem cell transplantation | Poster number: PS1629 Poster Session 2 Saturday, June 13, 6:45-7:45 pm Encore of data accepted for oral presentation at ASCO 2026 |
| Revumenib therapy post hematopoietic stem cell transplant for patients with relapsed/refractory KMT2Ar, NPM1m, and NUP98r acute myeloid leukemia: post hoc analysis of outcomes from AUGMENT-101 | Abstract Code: PS1631 Poster Session 2 Saturday, June 13, 6:45-7:45 pm |
| Relapsed/refractory | |
| Phase 1/2 study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in relapsed/refractory AML | Abstract Code: PF495 Poster Session 1 Friday, June 12, 6:45-7:45 pm |
| Long-term follow-up of pediatric/young adult patients with relapsed/refractory KMT2Ar acute leukemia treated with revumenib in AUGMENT-101 | Abstract Code: PF508 Poster Session 1 Friday, June 12, 6:45-7:45 pm |
| Efficacy of revumenib in acute myeloid leukemia harboring NPM1-mutated co-mutations: post hoc analysis of AUGMENT-101 | Abstract Code: PF514 Poster Session 1 Friday, June 12, 6:45-7:45 pm |
| Pharmacokinetic assessment of revumenib in patients with relapsed/refractory acute leukemias harboring a KMT2A rearrangement or NPM1 mutation: Impact of food and concomitant medications | Abstract Code: PF564 Poster Session 1 Friday, June 12, 6:45-7:45 pm Encore of data accepted for poster presentation at ASCO 2026 |
| Clinical activity of revumenib in patients with relapsed/refractory NUP98-rearranged acute leukemias | Abstract Code: PS1607 Poster Session 2 Saturday, June 13, 6:45-7:45 pm |
| Trials in progress | |
| A phase 3 study of revumenib in combination with intensive chemotherapy in patients with newly diagnosed NPM1-mutated acute myeloid leukemia (REVEAL-ND NPM1): Trial in progress | Abstract Code: PB2821 Publication only |
| Revumenib + venetoclax/azacitidine in adults with newly diagnosed NPM1m or KMT2Ar acute leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002): Trial in progress | Abstract Code: PB2796 Publication only |
| A phase 1/2 study of the menin inhibitor revumenib with the CELMod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias | Abstract Code: PS1658 Poster Session 2 Saturday, June 13, 6:45-7:45 pm |
About Revuforj® (revumenib)
Revuforj (revumenib) is an oral, first-in-class menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation as determined by an FDA-authorized test in adult and pediatric patients one year and older. Revuforj is also indicated for the treatment of R/R acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options.
Multiple trials of revumenib are ongoing or planned across the treatment landscape, including in combination with standard of care therapies in newly diagnosed patients with NPM1m or KMT2Ar AML.
Revumenib was previously granted Orphan Drug Designation for the treatment of AML, ALL and acute leukemias of ambiguous lineage (ALAL) by the U.S. FDA and for the treatment of AML by the European Commission. The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and Breakthrough Therapy Designation for the treatment of adult and pediatric patients with R/R acute leukemia harboring a KMT2A rearrangement.
Revuforj (revumenib)
IMPORTANT SAFETY INFORMATION
WARNING: DIFFERENTIATION SYNDROME, QTc PROLONGATION, and TORSADES DE POINTES
Differentiation syndrome, which can be fatal, has occurred with Revuforj. Signs and symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and renal dysfunction. If differentiation syndrome is suspected, immediately initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.
QTc prolongation and Torsades de Pointes have occurred in patients receiving Revuforj. Correct hypokalemia and hypomagnesemia prior to and during treatment. Do not initiate Revuforj in patients with QTcF > 450 msec. If QTc interval prolongation occurs, interrupt, reduce, or permanently discontinue Revuforj.
WARNINGS AND PRECAUTIONS
Differentiation Syndrome: Revuforj can cause fatal or life-threatening differentiation syndrome (DS). Symptoms of DS, including those seen in patients treated with Revuforj, include fever, dyspnea, hypoxia, peripheral edema, pleuropericardial effusion, acute renal failure, rash, and/or hypotension.
In clinical trials, DS occurred in 60 (
Reduce the white blood cell count to less than 25 Gi/L prior to starting Revuforj. If DS is suspected, immediately initiate treatment with systemic corticosteroids (e.g., dexamethasone 10 mg IV every 12 hours in adults or dexamethasone 0.25 mg/kg/dose IV every 12 hours in pediatric patients weighing less than 40 kg) for a minimum of 3 days and until resolution of signs and symptoms. Institute supportive measures and hemodynamic monitoring until improvement. Interrupt Revuforj if severe signs and/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids, or earlier if life-threatening symptoms occur such as pulmonary symptoms requiring ventilator support. Restart steroids promptly if DS recurs after tapering corticosteroids.
QTc Interval Prolongation and Torsades de Pointes: Revuforj can cause QT (QTc) interval prolongation and Torsades de Pointes.
Of the 241 patients treated with Revuforj at the recommended dosage for relapsed or refractory acute leukemia in clinical trials, QTc interval prolongation was reported as an adverse reaction in 86 (
Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to and throughout treatment with Revuforj. Perform an electrocardiogram (ECG) prior to initiation of Revuforj, and do not initiate Revuforj in patients with QTcF >450 msec. Perform an ECG at least once weekly for the first 4 weeks and at least monthly thereafter. In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring may be necessary. Concomitant use with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation.
- Interrupt Revuforj if QTcF increases >480 msec and <500 msec, and restart Revuforj at the same dose twice daily after the QTcF interval returns to ≤480 msec
- Interrupt Revuforj if QTcF increases >500 msec or by >60 msec from baseline, and restart Revuforj twice daily at the lower-dose level after the QTcF interval returns to ≤480 msec
- Permanently discontinue Revuforj in patients with ventricular arrhythmias and in those who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia
Embryo-Fetal Toxicity: Revuforj can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Revuforj and for 4 months after the last dose of Revuforj.
ADVERSE REACTIONS
Fatal adverse reactions occurred in 9 (
Serious adverse reactions were reported in 184 (
The most common adverse reactions (≥
DRUG INTERACTIONS
Drug interactions can occur when Revuforj is concomitantly used with:
- Strong CYP3A4 inhibitors: reduce Revuforj dose
- Strong or moderate CYP3A4 inducers: avoid concomitant use with Revuforj
- QTc-prolonging drugs: avoid concomitant use with Revuforj. If concomitant use is unavoidable, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold Revuforj if the QTc interval is >480 msec. Restart Revuforj after the QTc interval returns to ≤480 msec
SPECIFIC POPULATIONS
Lactation: advise lactating women not to breastfeed during treatment with Revuforj and for 1 week after the last dose.
Pregnancy and testing: Revuforj can cause fetal harm when administered to a pregnant woman. Verify pregnancy status in females of reproductive potential within 7 days prior to initiating Revuforj.
Infertility: based on findings in animals, Revuforj may impair fertility. The effects on fertility were reversible.
Pediatric: monitor bone growth and development in pediatric patients.
Geriatric: no overall differences were observed in the effectiveness of Revuforj between patients who were 65 years and older, and younger patients. Compared to younger patients, the incidences of QTc prolongation and edema were higher in patients 65 years and older.
To report SUSPECTED ADVERSE REACTIONS, contact Syndax Pharmaceuticals at 1-888-539-3REV or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see Full Prescribing Information, including BOXED WARNINGS.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, the acceptance of Syndax and its partners' products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj's or Niktimvo’s commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
